Genpharm International — 26 certified H-1B filings (FY2016–FY2023)
- 7
- Filings · FY2023
- $146k
- Median base · FY2023
- Research Associate III
- Top role · 3 all-time
- CA
- Top state · 26 all-time
Genpharm International filed 7 certified H-1B LCAs in FY2023 (up 133% from the year before), with a median base salary of $146k and the middle 50% of offers between $122k and $149k. That is 32% above the market median for the same job titles. Across all years it has 26 certified filings since FY2016, most often for Research Associate III in California.
How much does Genpharm International pay H-1B workers?
Certified base salary by fiscal year: each box is the p25–p75 range, the heavy line the median, the whiskers reach p10–p90. $146k median in FY2023. Base pay only — hover a year for its figures.
How has Genpharm International's H-1B hiring changed by year?
1 certified filings in FY2016 → 7 in FY2023. The change column is each year against the one before.
| Fiscal year | Filings | vs prior FY | Median base |
|---|---|---|---|
| FY2023 | 7 | +133% | $146k |
| FY2022 | 3 | +50% | $130k |
| FY2021 | 2 | −60% | $106k |
| FY2020 | 5 | +67% | $126k |
| FY2019 | 3 | +200% | $110k |
| FY2018 | 1 | −75% | $82k |
| FY2017 | 4 | +300% | $93k |
| FY2016 | 1 | — | $105k |
Which wage levels does Genpharm International file?
DOL prevailing-wage levels I–IV approximate experience tiers (I = entry, IV = fully competent). 33% of Genpharm International's filings sit at Level III–IV. A heavy I–II skew reads as entry-level or contractor-style hiring; a heavy IV skew as senior in-house roles — and higher levels earn more lottery entries.
Share of 24 filings with a wage level · all years
- Level I12.5%3
- Level II54.2%13
- Level III25.0%6
- Level IV8.3%2
What jobs does Genpharm International sponsor for H-1B?
The most-filed job titles across all years (DOL titles, employer pay-grade codes stripped), with base-salary percentiles.
| Job title | Filings | Median base |
|---|---|---|
| Research Associate III | 3 | $82k |
| Scientist | 3 | $122k |
| Senior Scientist | 2 | $146k |
| Research Investigator I | 2 | $132k |
| Mass Spectrometry and Data Analysis Scientist | 1 | $130k |
| Principal Scientist | 1 | $149k |
| Principal Technical Lead | 1 | $160k |
| Research Associate IV | 1 | $100k |
| Research Investigator | 1 | $110k |
| Research Investigator III | 1 | $102k |
Where does Genpharm International hire H-1B workers?
Worksite states on the certified filings, all years. Deeper pink = more filings; hover a state for its figures.
| State | Filings | Median base |
|---|---|---|
| CA | 26 | $122k |
What has Genpharm International filed recently?
Every certified LCA on record for Genpharm International: job title, worksite, prevailing-wage level and the offered base salary.
| FY | Job title | Base salary |
|---|---|---|
| 2023 | Senior Scientist, Machine Learning | $159,185 |
| 2023 | Scientist, Biochemistry, Leads Discovery and Optimization | $128,533 |
| 2023 | Senior Scientist | $145,859 |
| 2023 | Scientist | $121,928 |
| 2023 | Senior Scientist | $145,860 |
| 2023 | Scientist | $121,928 |
| 2023 | Principal Scientist | $148,756 |
| 2022 | Scientist | $132,613 |
| 2022 | Mass Spectrometry and Data Analysis Scientist | $129,780 |
| 2022 | Senior Associate Scientist | $115,000 |
| 2021 | Associate Research IV - Scientist | $127,308 |
| 2021 | Associate Research Scientist 2 | $106,090 |
| 2020 | Research Investigator I | $135,000 |
| 2020 | Research Scientist 2 | $125,660 |
| 2020 | Research Investigator I | $132,000 |
| 2020 | Associate Research Scientist I | $95,000 |
| 2020 | Research Scientist I | $120,000 |
| 2019 | Research Investigator III | $102,167 |
| 2019 | Research Investigator | $110,000 |
| 2019 | Associate Scientist | $130,000 |
| 2018 | Research Associate III | $82,427 |
| 2017 | Research Associate III | $93,071 |
| 2017 | Principal Technical Lead | $160,329 |
| 2017 | Research Associate IV | $100,000 |
| 2017 | Research Associate III | $80,000 |
| 2016 | Scientist I | $105,000 |
Common questions about Genpharm International's H-1B filings
- How much does Genpharm International pay H-1B workers?
- Genpharm International's median certified H-1B base salary is $146k (FY2023), from 7 filings. See the full salary distribution and percentiles above.
- How many H-1B workers does Genpharm International sponsor?
- Genpharm International has 26 certified H-1B Labor Condition Applications on record (FY2016–FY2023).
- What jobs does Genpharm International sponsor for H-1B?
- Genpharm International's most-sponsored H-1B roles include Research Associate III, Scientist, Senior Scientist, Research Investigator I.
- Where does Genpharm International hire H-1B workers?
- Genpharm International's top H-1B worksite states are CA.
- Does a certified LCA mean an H-1B visa was approved?
- No. A Labor Condition Application (LCA) is the Department of Labor attestation an employer must have certified before filing an H-1B petition with USCIS. It records the job, worksite and offered wage, but not whether the petition was filed, selected in the lottery, or approved. Filing counts measure intent to sponsor, not headcount.
- What salary do these figures show?
- The base annual wage offered on the certified LCA, converted to a yearly amount. Bonus, equity, overtime and benefits are not included, so total compensation is typically higher. Figures are medians and percentiles over certified filings; wages above $5,000,000 a year are excluded as data-entry errors.
- What do prevailing-wage levels I–IV mean?
- The Department of Labor assigns each LCA an OES wage level from I (entry) to IV (fully competent) for the occupation and area. Under the FY2027 wage-weighted H-1B lottery rule, a higher level earns more selection entries, so an employer's level mix is a proxy for how senior its sponsored roles are.
Keep exploring
Calculate your H-1B lottery odds →orCheck out the insights →
Source: U.S. Department of Labor, Office of Foreign Labor Certification — certified LCA disclosure data through June 2026 (FY2016–FY2023). An LCA is not an approved visa; pay figures are base salary and exclude bonus and equity. Methodology →